Kevin joined EQT Life Sciences (LS) Amsterdam office as an Associate in July 2022. Prior to EQT LS, Kevin worked in R&D at BioMarin Pharmaceutical with a focus on clinical pharmacology, PK/PD and pharmacometrics. While at BioMarin, he contributed to the approval of several therapies including Roctavian (AAV5 gene therapy for hemophilia A), and Palynziq (biologic for phenylketonuria). Prior to BioMarin, Kevin worked in Amgen's Clinical Pharmacology Modelling and Simulation group.  Kevin has an MBA from INSEAD,  and a B.S. in Pharmacology from the University of California, Santa Barbara.